FY2025 · ended Nov 30, 2025 · Revenue $83.98M, +54.0% YoY · Filed Jan 28, 2026
Nurix Therapeutics, Inc. (NRIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Nov 30, 2025, it reported revenue of $84.0 million and a net loss of $264.5 million. Free cash flow was -$263.5 million. As of Aug 31, 2026 it held $720.2 million in cash and investments and $65.3 million in total debt.
Revenue (TTM)
$701.94M
+738.8% vs year-ago TTM
Net income (TTM)
$294.88M
+220.5% vs year-ago TTM
Operating cash flow (TTM)
$379.31M
+264.6% vs year-ago TTM
Free cash flow (TTM)
$369.81M
+253.2% vs year-ago TTM
EPS (TTM)
$2.69
+190.7% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
102.84M
+35.5% vs prior year
Net cash
$654.91M
as of Aug 31, 2026
Operating margin
41.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRIX (Nasdaq)
- Fiscal year ends
- November 30
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1549595
- Former names
- Nurix, Inc. (until Sep 18, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Nov 30, 2025 |
FY 2024 Nov 30, 2024 |
FY 2023 Nov 30, 2023 |
FY 2022 Nov 30, 2022 |
FY 2021 Nov 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M |
| Diluted EPS | -$3.05 | -$2.88 | -$2.65 | -$3.71 | — |
| Operating cash flow | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M |
| Stockholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M |
| Cash and investments | $247.0M | $110.0M | $54.6M | $373.0M | $432.9M |
| Total debt | $55.7M | $28.3M | $30.6M | $12.0M | $13.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Oct 13, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Jul 9, 2026 | May 31, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 9, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
All 561 Nurix Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.